BECOME A MEMBER - Get Unlimited CE

  • SIGN IN
  • GET HELP
    •  

    Webinar Details

    Event Type

    Live Online

    Date

    Friday, December 11, 2020

    Time

    2:00 PM - 3:00 PM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    1 Contact Hour(s)

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Early studies show that patients with COVID-19 appear to be at a higher risk for thrombotic complications like venous thromboembolism (VTE).  VTE is already among the leading causes of death from cardiovascular disease.  So, in addition to the traditional risk factors for VTE, practitioners must consider both the indirect effects as well as the direct effects of the COVID infection as they contribute to even greater risk of the consequences of VTE. This program will review the current literature and evidence regarding the frequency of VTE in patients with COVID, as well as the available guidance and evidence-based literature regarding the use of anticoagulation therapies in patients with COVID or patients recovering from COVID.


      Handouts

      Slide Document 20256L01_6pp.pdf
      Slide Document 20256L01_2pp.pdf





      Financial Support By

      Bristol-Myers Squibb and Pfizer Alliance

    • Pharmacist

      Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.
      Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.

      Nurse

      Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.
      Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.

    • Repeat Presentation

      This presentation was last given on 12/15/2020 8:00 PM

      Future Airings

      Date Time
      Tuesday, December 15, 2020 8:00 PM View

    • Activity Type

      Application

      CE Broker

      20-791208

      Universal Activity Number

      Pharmacist 0798-0000-20-256-L01-P

      Nurse 0798-0000-20-256-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Windows 8.1
    Windows 10
    Apple Mac OS X 10.13 or higher
    iOS 10+
    Android 4.3+


    SOFTWARE REQUIREMENTS
    Google Chrome
    Mozilla Firefox

    Log in locally; do not log in using a VPN, cloud server, remote desktop, etc.


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon. Through this notice, PharmCon. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.

     

    LEARN

    LIVE CE

    HOME STUDY CE

    SERIES CERTIFICATION

    SUPPORT

    ABOUT

    RESOURCES

    CE REPORTING

    CAREER ASSISTANCE

    PATIENT CARE INFO

     

    CE ACTIVITY

    ACCOUNT

    (843) 488 5550 Office

    (843) 488 5554 Fax

    support@freeCE.com Email

    www.freeCE.com Web

    201 N. King of Prussia Rd, Suite 370
    Radnor, PA 19807     Address


     

    ©  PharmCon All Rights Reserved.

    Terms & Conditions

    Privacy Policy

    freeCE is a division of PharmCon